SEC Form 4 · accession 0001209191-19-007245
Acer Therapeutics Inc. · ACER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chris Schelling
Officer — President and Chief Executive · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 2:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001069308
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $24.46 | Feb 1, 2019 | A | 72,500 | A | — | Feb 1, 2029 | Common Stock | 72,500 | 72,500 | D |
Explanation of responses
- F1The option vests and becomes exercisable over four years as follows: 25% of the shares vest on February 1, 2020, and 1/16th of the shares vest each quarter thereafter for the remaining three years.